Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Maribavir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,940Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Japan Approves First Post-Transplant Anti-Cytomegalovirus Infection Treatment
    Japan Approves First Post-Transplant Anti-Cytomegalovirus Infection Treatment

    24 Jun 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/24475/japan-approves-first-post-transplant-anti-cytomegalovirus-infection-treatment.html

    BIOSPECTRUM ASIA
    24 Jun 2024
    Share Share
    Takeda Announces China NMPA Approval of LIVTENCITY for the Treatment of CMV
    Takeda Announces China NMPA Approval of LIVTENCITY for the Treatment of CMV

    21 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231221976317/en

    BUSINESSWIRE
    21 Dec 2023
    Share Share
    Takeda Pharmaceuticals' Livtencity (maribavir) Approved In Europe
    Takeda Pharmaceuticals' Livtencity (maribavir) Approved In Europe

    05 Jul 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/livtencity-epar-medicine-overview_en.pdf

    EMA
    05 Jul 2023
    Share Share
    Takeda Pharmaceuticals' Livtencity (Maribavir) Receives Approval in Europe
    Takeda Pharmaceuticals' Livtencity (Maribavir) Receives Approval in Europe

    17 Mar 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/livtencity-epar-medicine-overview_en.pdf

    EMA
    17 Mar 2023
    Share Share
    Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Effect in CMV
    Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Effect in CMV

    19 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221219005011/en

    BUSINESSWIRE
    19 Dec 2022
    Share Share
    NICE recommends LIVTENCITY for the treatment of adults with post-transplant CMV
    NICE recommends LIVTENCITY for the treatment of adults with post-transplant CMV

    09 Dec 2022

    // BIONJ

    https://bionj.org/news/pr-newswire-global?rkey=20221208EN60190&filter=16221

    BIONJ
    09 Dec 2022
    Share Share